ATE323149T1 - Paramyxovirus-vektor zum gentransfer ins kardiovaskuläre system - Google Patents

Paramyxovirus-vektor zum gentransfer ins kardiovaskuläre system

Info

Publication number
ATE323149T1
ATE323149T1 AT01981031T AT01981031T ATE323149T1 AT E323149 T1 ATE323149 T1 AT E323149T1 AT 01981031 T AT01981031 T AT 01981031T AT 01981031 T AT01981031 T AT 01981031T AT E323149 T1 ATE323149 T1 AT E323149T1
Authority
AT
Austria
Prior art keywords
cardiovascular system
vector
gene transfer
paramyxovirus vector
paramyxovirus
Prior art date
Application number
AT01981031T
Other languages
English (en)
Inventor
Uta Griesenbach
Stefano Ferrari
Duncan M Geddes
Eric Wfw Alton
Mamoru Hasegawa
Xiaogang Hou
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Application granted granted Critical
Publication of ATE323149T1 publication Critical patent/ATE323149T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01981031T 2000-11-08 2001-11-08 Paramyxovirus-vektor zum gentransfer ins kardiovaskuläre system ATE323149T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000339942A JP2002142770A (ja) 2000-11-08 2000-11-08 循環系への遺伝子送達用パラミクソウイルスベクター

Publications (1)

Publication Number Publication Date
ATE323149T1 true ATE323149T1 (de) 2006-04-15

Family

ID=18814933

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01981031T ATE323149T1 (de) 2000-11-08 2001-11-08 Paramyxovirus-vektor zum gentransfer ins kardiovaskuläre system

Country Status (12)

Country Link
US (1) US20040101965A1 (de)
EP (2) EP1334174B1 (de)
JP (1) JP2002142770A (de)
KR (1) KR100852078B1 (de)
CN (1) CN1555417B (de)
AT (1) ATE323149T1 (de)
AU (1) AU2002212733A1 (de)
CA (1) CA2428073C (de)
DE (1) DE60118771T2 (de)
DK (1) DK1334174T3 (de)
ES (1) ES2260301T3 (de)
WO (1) WO2002038726A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
CN1367839A (zh) 1999-09-06 2002-09-04 株式会社载体研究所 含有已改变的转录起始序列的副粘病毒
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
US20020002143A1 (en) 2000-03-30 2002-01-03 Munehide Kano AIDS virus vaccines using sendai virus vector
KR100807016B1 (ko) * 2000-06-01 2008-02-25 가부시키가이샤 디나벡크 겐큐쇼 헤마글루티닌 활성을 갖는 막단백질을 포함하는 슈도타입레트로바이러스 벡터
KR20030014392A (ko) * 2000-06-27 2003-02-17 가부시키가이샤 디나벡크 겐큐쇼 신장세포에 유전자를 도입하기 위한 바이러스 벡터
WO2002031138A1 (en) * 2000-10-06 2002-04-18 Dnavec Research Inc. Paramyxovirus vector for transferring foreign gene into skeletal muscle
DE60133767T2 (de) * 2000-11-27 2009-06-25 Dnavec Research Inc., Tsukuba Für fibroblasten-wachstumsfaktor 2 (fgf2) kodierender paramyxovirus-vektor und dessen verwendung
WO2003092738A1 (en) * 2002-04-30 2003-11-13 Dnavec Research Inc. Drug- or gene-carrier composition having lowered hemagglutinin activity
JPWO2004022731A1 (ja) * 2002-09-04 2005-12-22 株式会社ディナベック研究所 シアル酸結合活性を有する膜蛋白質をエンベロープに含むウイルスベクターをグラム陽性菌由来ノイラミニダーゼを用いて製造する方法
AU2003275581A1 (en) * 2002-10-24 2004-05-13 Dnavec Research Inc. Method of transferring gene into t cells
EP1642966B1 (de) * 2003-06-30 2010-03-03 Dnavec Research Inc. Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
AU2005205441A1 (en) * 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
WO2005071085A1 (ja) * 2004-01-22 2005-08-04 Dnavec Research Inc. ウイルスベクターの製造方法
JPWO2005097988A1 (ja) * 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
KR20080031167A (ko) * 2005-04-20 2008-04-08 디나벡크 가부시키가이샤 알츠하이머병 치료용의 고도로 안전한 비강투여용 유전자백신
CA2612168A1 (en) * 2005-06-14 2006-12-21 Dnavec Corporation Methods for producing antibodies
HUE028512T2 (en) * 2005-10-28 2016-12-28 Id Pharma Co Ltd Gene transfer to airway epithelial stem cell using RNA virus spike protein pseudotyped lentiviral vector
KR20080094910A (ko) * 2006-01-17 2008-10-27 디나벡크 가부시키가이샤 신규 단백질 발현계
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
JPS6147186A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147185A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6562596B1 (en) * 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
EP1394259A3 (de) * 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
KR100754091B1 (ko) 1995-10-31 2007-08-31 가부시끼가이샤 디나벡 겡뀨쇼 자율 복제 능력을 갖는 (-)쇄 ｒｎａ 바이러스 벡터
AU7335296A (en) * 1995-11-01 1997-05-22 Dnavec Research Inc. Recombinant sendai virus
KR100461701B1 (ko) 1996-02-29 2005-04-06 다카라 바이오 가부시키가이샤 바이러스의정제및제거방법
US5833651A (en) * 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
EP0953647B1 (de) * 1996-12-16 2008-05-28 Eisai R&D Management Co., Ltd. Verfahren zur herstellung von retroviralen vektoren für die gentherapie
CA2205076A1 (en) * 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
FR2766706B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
US5962274A (en) * 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
DE69933528T2 (de) * 1998-11-09 2007-08-09 Nippon Biologicals, Inc. Verfahren zur Cytokinproduktionn unter Verwendung eines Sendai Virus Expressionssystems
JP2000201689A (ja) * 1998-11-09 2000-07-25 Nippon Bio Capital Limited:Kk センダイウイルス発現系を用いたサイトカインの製造方法
JP2000253876A (ja) * 1999-03-08 2000-09-19 Dnavec Research Inc センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
DK1186667T3 (da) 1999-05-18 2007-10-22 Dnavec Research Inc Kappegendeficient virusvektor af Paramyxoviridae
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
ATE399206T1 (de) 1999-05-18 2008-07-15 Dnavec Research Inc Ribonukleoproteinkomplex aus paramyxovirus
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
EP1067179A1 (de) 1999-07-09 2001-01-10 Pierre Fabre Medicament Verfahren zur Selektion von attenuierten Paramyxoviridae verwenbare als Impstoffen und Therapeutika
CN1367839A (zh) 1999-09-06 2002-09-04 株式会社载体研究所 含有已改变的转录起始序列的副粘病毒
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
KR100774796B1 (ko) * 2000-01-19 2007-11-07 가부시키가이샤 디나벡크 겐큐쇼 파라믹소바이러스 벡터의 혈관으로의 유전자 도입용도
US20020002143A1 (en) * 2000-03-30 2002-01-03 Munehide Kano AIDS virus vaccines using sendai virus vector
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
KR100807016B1 (ko) * 2000-06-01 2008-02-25 가부시키가이샤 디나벡크 겐큐쇼 헤마글루티닌 활성을 갖는 막단백질을 포함하는 슈도타입레트로바이러스 벡터
KR20030014392A (ko) * 2000-06-27 2003-02-17 가부시키가이샤 디나벡크 겐큐쇼 신장세포에 유전자를 도입하기 위한 바이러스 벡터
WO2002031138A1 (en) * 2000-10-06 2002-04-18 Dnavec Research Inc. Paramyxovirus vector for transferring foreign gene into skeletal muscle
DE60133767T2 (de) * 2000-11-27 2009-06-25 Dnavec Research Inc., Tsukuba Für fibroblasten-wachstumsfaktor 2 (fgf2) kodierender paramyxovirus-vektor und dessen verwendung
AU2003275581A1 (en) * 2002-10-24 2004-05-13 Dnavec Research Inc. Method of transferring gene into t cells
CN1768145A (zh) * 2003-01-31 2006-05-03 株式会社载体研究所 编码核酶的副粘病毒载体及其应用
EP1642966B1 (de) * 2003-06-30 2010-03-03 Dnavec Research Inc. Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
AU2004286144A1 (en) * 2003-11-04 2005-05-12 Dnavec Research Inc. Method for producing gene transferred dendritic cells
AU2005205441A1 (en) * 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
JPWO2005097988A1 (ja) * 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
KR20080031167A (ko) * 2005-04-20 2008-04-08 디나벡크 가부시키가이샤 알츠하이머병 치료용의 고도로 안전한 비강투여용 유전자백신

Also Published As

Publication number Publication date
DK1334174T3 (da) 2006-06-26
ES2260301T3 (es) 2006-11-01
JP2002142770A (ja) 2002-05-21
WO2002038726A3 (en) 2003-03-20
US20040101965A1 (en) 2004-05-27
CN1555417A (zh) 2004-12-15
EP1662003A3 (de) 2006-06-14
HK1070100A1 (zh) 2005-06-10
EP1334174B1 (de) 2006-04-12
KR20030074617A (ko) 2003-09-19
EP1334174A2 (de) 2003-08-13
AU2002212733A1 (en) 2002-05-21
CA2428073A1 (en) 2002-05-16
CN1555417B (zh) 2010-04-28
CA2428073C (en) 2012-01-10
WO2002038726A2 (en) 2002-05-16
DE60118771D1 (de) 2006-05-24
KR100852078B1 (ko) 2008-08-13
EP1662003A2 (de) 2006-05-31
DE60118771T2 (de) 2007-04-12

Similar Documents

Publication Publication Date Title
ATE323149T1 (de) Paramyxovirus-vektor zum gentransfer ins kardiovaskuläre system
WO2001012824A8 (en) Means and methods for modifying gene expression using unpolyadenylated rna
CA2185712A1 (en) Enhanced virus-mediated dna transfer
DE69333529D1 (de) Pflanzenvirus-vektor, plasmid, methode der expression fremder gene und methode zur gewinnung obiger genprodukte
DE60143718D1 (de) Vektorkonstruktionen
WO2003068961A3 (en) Method to modify differentiation of pluripotential stem cells
Schlesinger et al. Mechanisms involved in natural and experimental neuropathogenicity of influenza viruses: evidence and speculation
NO20034237L (no) Ny fremgangsmate for den industrielle syntese av metyldiesteren av 5-amino-3-karboksymetyl-4-cyano-2-tiofenkarboksylsyre, og anvendelse i syntesen av bivalente salter av ranelinsyre og deres hydrater
MXPA02012255A (es) Secuencia de nucleotidos del genoma a/udorn/72(hen2) de influenza.
HRP20050424A2 (en) Process for making risperidone and intermediates thereof
WO2002002766A3 (en) Natural promoters for gene expression and metabolic monitoring in bacillus species
DE50110723D1 (de) Isolierte luziferasen sowie deren verwendung
WO2007125445A3 (en) An array of swim care articles and method for providing same to shopper and retailer
ATE428793T1 (de) Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
HUP0204093A2 (hu) Ciroktörpítő gének és alkalmazásuk
DK1283868T3 (da) Isoleret gum-operon fra Xyllela fastidiosa, isolerede nukleinsyremolekyler derfra og anvendelser deraf
WO2001094588A3 (en) Gene (cur) related to a curly phenotype in plants
DK1597376T3 (da) RNA-polymerase I-promotor fra höns samt anvendelse heraf
FR2814536B1 (fr) Enceinte a temperature regulee pour la conservation de produits notamment des bouteilles de vin
EP1086116A4 (de) Zusammensetzungen und verfahren für den pulmonativen transport von nuklein-säuren
BR0003561A (pt) Processo para a preparação fermentativa de produtos metabólicos e para as sequências de nucleotìdeos codificando para o gene sod
HK1043155A1 (zh) 噬菌體t4基因35的基因及蛋白質排列
Gilchrist Colour application technology
ATE400583T1 (de) Neues gen, welches bei der krankheit apeced defekt ist, und dessen verwendungen
Laue et al. Growth stimulation of Staphylococcus aureus by L-cystine or L-djenkolic acid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1334174

Country of ref document: EP

REN Ceased due to non-payment of the annual fee